You just read:

Scottish Medicines Consortium Accepts TARGAXAN® 550 ▼ (RIFAXIMIN-α) Cost-Effectiveness[i] - A New Treatment for a Life-Threatening Condition Linked to Liver Disease

News provided by

Norgine ltd

09 Sep, 2013, 15:26 BST